☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 85-2609730 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Units, each consisting of one share of Common Stock and one-half of one redeemable warrant | ASAXU | The Nasdaq Stock Market LLC | ||
Common Stock, par value $0.0001 per share | ASAX | The Nasdaq Stock Market LLC | ||
Redeemable warrants, exercisable for shares of Common Stock at an exercise price of $11.50 per share | ASAXW | The Nasdaq Stock Market LLC |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||||
Emerging growth company | ☒ |
Page | |||||||
1 | |||||||
1 | |||||||
2 | |||||||
3 | |||||||
4 | |||||||
5 | |||||||
21 | |||||||
21 | |||||||
22 | |||||||
23 | |||||||
23 | |||||||
24 | |||||||
25 | |||||||
Item 1. Interim Financial Statements. |
September 30, 2021 | December 31, 2020 | |||||||
(Unaudited) (Restated) | ||||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 51,562 | $ | 0— | ||||
Prepaid expenses | 503,361 | 0— | ||||||
Total Current Assets | 554,923 | 0— | ||||||
Deferred offering costs | 0— | 110,125 | ||||||
Cash and marketable securities held in Trust Account | 172,550,024 | 0— | ||||||
TOTAL ASSETS | $ | 173,104,947 | $ | 110,125 | ||||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
Current liabilities | ||||||||
Accrued expenses | $ | 359,436 | $ | 450 | ||||
Promissory note – related party | 425,000 | 85,302 | ||||||
Total Current Liabilities | 784,436 | 85,752 | ||||||
Warrant liabilities | 396,625 | 0— | ||||||
Total Liabilities | 1,181,061 | 85,752 | ||||||
Commitments | 0 | 0 | ||||||
Common stock subject to possible redemption; $0.0001 par value; 17,250,000 and 0no shares at redemption value as of September 30, 2021 and December 31, 2020, respectively | 172,500,000 | 0— | ||||||
Stockholders’ (Deficit) Equity | ||||||||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; 0000none issued or outstanding | 0— | 0— | ||||||
Common stock, $0.0001 par value; 50,000,000 shares authorized; 4,787,500 and 4,312,500 shares issued and outstanding (excluding 17,250,000 and 0no shares subject to possible redemption) as of September 30, 2021 and December 31, 2020, respectively (1) | 479 | 431 | ||||||
Additional paid-in capital | 554,160 | 24,569 | ||||||
Accumulated deficit | (1,130,753 | ) | (627 | ) | ||||
Total Stockholders’ (Deficit) Equity | (576,114 | ) | 24,373 | |||||
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $ | 173,104,947 | $ | 110,125 | ||||
March 31, 2022 | December 31, 2021 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 30,094 | $ | 67,689 | ||||
Prepaid expenses | 255,933 | 344,659 | ||||||
Total Current Assets | 286,027 | 412,348 | ||||||
Cash and marketable securities held in Trust Account | 172,625,112 | 172,561,080 | ||||||
TOTAL ASSETS | $ | 172,911,139 | $ | 172,973,428 | ||||
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
Current liabilities | ||||||||
Accrued expenses | $ | 349,884 | $ | 459,988 | ||||
Promissory note – related party | 1,140,000 | 750,000 | ||||||
Total Current Liabilities | 1,489,884 | 1,209,988 | ||||||
Warrant liabilities | 40,114 | 342,190 | ||||||
Total Liabilities | 1,529,998 | 1,552,178 | ||||||
Commitments | 0 | 0 | ||||||
Common stock subject to possible redemption; $0.0001 par value; 17,250,000 shares at redemption value as of March 31, 2022 and December 31, 2021 | 172,500,000 | 172,500,000 | ||||||
Stockholders’ Deficit | ||||||||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; NaN issued or outstanding | — | — | ||||||
Common stock, $0.0001 par value; 50,000,000 shares authorized; 4,787,500 shares issued and outstanding (excluding 17,250,000 shares subject to possible redemption) as of March 31, 2022 and December 31, 2021 | 479 | 479 | ||||||
Additional paid-in capital | 554,160 | 554,160 | ||||||
Accumulated deficit | (1,673,498 | ) | (1,633,389 | ) | ||||
Total Stockholders’ Deficit | (1,118,859 | ) | (1,078,750 | ) | ||||
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ | 172,911,139 | $ | 172,973,428 | ||||
Three Months Ended September 30, 2021 | Nine Months Ended September 30, 2021 | For the Period from August 11, 2020 (Inception) Through September 30, 2020 | Three Months Ended March 31, | |||||||||||||||||
(Restated) | 2022 | 2021 | ||||||||||||||||||
Formation and operating costs | $ | 578,271 | $ | 1,087,835 | $ | 177 | ||||||||||||||
Operating and formation costs | $ | 406,217 | $ | 220,267 | ||||||||||||||||
Loss from operations | (578,271 | ) | (1,087,835 | ) | (177 | ) | (406,217 | ) | (220,267 | ) | ||||||||||
Other income (expense): | ||||||||||||||||||||
Interest earned on marketable securities held in Trust Account | 19,788 | 49,479 | 0— | 44,835 | 10,390 | |||||||||||||||
Unrealized gain on marketable securities held in Trust Account | 545 | 545 | 19,197 | — | ||||||||||||||||
Interest income – bank | 2 | 8 | 0— | |||||||||||||||||
Change in fair value of warrant liability | (239,875 | ) | (209,000 | ) | 0— | 302,076 | 52,250 | |||||||||||||
Change in fair value of overallotment liability | 0— | 134,105 | ||||||||||||||||||
Change in fair value of over-allotment option liability | 0— | 134,105 | ||||||||||||||||||
Transaction costs associated with Initial Public Offering | 0— | (17,428 | ) | 0— | 0— | (17,428 | ) | |||||||||||||
Total other expense, net | (219,540 | ) | $ | (42,291 | ) | 0— | ||||||||||||||
Total other income, net | 366,108 | $ | 179,317 | |||||||||||||||||
Net loss | $ | (797,811 | ) | $ | (1,130,126 | ) | $ | (177 | ) | $ | (40,109 | ) | $ | (40,950 | ) | |||||
Basic and diluted weighted average shares outstanding, Common stock | 22,037,500 | $ | 19,320,330 | 3,750,000 | 22,037,500 | $ | 13,795,417 | |||||||||||||
Basic and diluted net loss per share, Common stock | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | |||||
Common Stock | Additional Paid in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |||||||||||||||||
Shares | Amount | |||||||||||||||||||
Balance – January 1, 2022 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (1,633,389 | ) | $ | (1,078,750 | ) | |||||||||
Net loss | — | — | — | (40,109 | ) | (40,109 | ) | |||||||||||||
Balance – March 31, 2022 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (1,673,498 | ) | $ | (1,118,859 | ) | |||||||||
Common Stock | Additional Paid in | Accumulated | Total Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Equity (Deficit) | ||||||||||||||||
Balance – January 1, 2021 | 4,312,500 | $ | 431 | $ | 24,569 | $ | (627 | ) | $ | 24,373 | ||||||||||
Fair value of Public Warrants | — | — | 6,780,799 | 0— | 6,780,799 | |||||||||||||||
Sale of 475,000 Private Placement Units | 475,000 | 48 | 4,562,894 | 0— | 4,562,942 | |||||||||||||||
Elimination of over-allotment option liability | — | — | 614,257 | 0— | 614,257 | |||||||||||||||
Allocated value of transaction costs to warrants | — | — | (165,442 | ) | 0— | (165,442 | ) | |||||||||||||
Accretion of common stock to redemption value | — | 0— | (11,262,350 | ) | 0— | (11,262,350 | ) | |||||||||||||
Net loss | — | 0— | 0— | (40,950 | ) | (40,950 | ) | |||||||||||||
Balance – March 31, 2021 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (41,577 | ) | $ | 513,062 | ||||||||||
Net loss | — | 0— | 0— | (291,365 | ) | (291,365 | ) | |||||||||||||
Balance – June 30, 2021 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (332,942 | ) | $ | 221,697 | ||||||||||
Net loss | — | 0— | 0— | (797,811 | ) | (797,811 | ) | |||||||||||||
Balance – September 30, 2021 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (1,130,753 | ) | $ | (576,114 | ) | |||||||||
Common Stock | Additional Paid in | Accumulated | Total Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
Balance – August 11, 2020 (Inception) | 0— | $ | 0— | $ | 0— | $ | 0— | $ | 0— | |||||||||||
Issuance of common stock to Sponsor | 4,312,500 | 431 | 24,569 | 0— | 25,000 | |||||||||||||||
Net loss | — | 0— | 0— | (177 | ) | (177 | ) | |||||||||||||
Balance – September 30, 2020 | 4,312,500 | $ | 431 | $ | 24,569 | $ | (177 | ) | $ | 24,823 | ||||||||||
Common Stock | Additional Paid in Capital | Accumulated Deficit | Total Stockholders’ Equity | |||||||||||||||||
Shares | Amount | |||||||||||||||||||
Balance – January 1, 2021 | 4,312,500 | $ | 431 | $ | 24,569 | $ | (627 | ) | $ | 24,373 | ||||||||||
Accretion of Common Stock to redemption value | — | 0— | (11,262,350 | ) | 0— | (11,262,350 | ) | |||||||||||||
Sale of 475,000 Private Placement Units | 475,000 | 48 | 4,562,327 | 0— | 4,562,942 | |||||||||||||||
Fair value of Public Warrants | — | — | 6,780,799 | 0— | 6,780,799 | |||||||||||||||
Allocated value of transaction costs to warrants | — | — | (165,442 | ) | 0— | (165,442 | ) | |||||||||||||
Elimination of over-allotment option liability | — | — | 614,257 | 0— | 614,257 | |||||||||||||||
Net loss | — | — | — | (40,950 | ) | (40,950 | ) | |||||||||||||
Balance – March 31, 2021 | 4,787,500 | $ | 479 | $ | 554,160 | $ | (41,577 | ) | $ | 513,062 | ||||||||||
Nine Months Ended September 30, | For the Period from August 11, 2020 (Inception) through September 30, | |||||||||||||||
2021 | 2020 | Three Months Ended March 31, | ||||||||||||||
(Restated) | 2022 | 2021 | ||||||||||||||
Cash Flows from Operating Activities: | ||||||||||||||||
Net loss | $ | (1,130,126 | ) | $ | (177 | ) | $ | (40,109 | ) | $ | (40,950 | ) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||
Change in fair value of warrant liabilities | 209,000 | 0— | (302,076 | ) | (52,250 | ) | ||||||||||
Change in fair value of overallotment liabilities | (134,105 | ) | 0— | |||||||||||||
Interest earned on marketable securities held in Trust Account | (49,479 | ) | 0— | (44,835 | ) | (10,390 | ) | |||||||||
Unrealized gain on marketable securities held in Trust Account | (545 | ) | 0— | (19,197 | ) | 0— | ||||||||||
Transaction costs associated with Initial Public Offering | 17,428 | 0— | ||||||||||||||
Change in fair value of over-allotment option liability | 0— | (134,105 | ) | |||||||||||||
Transaction costs incurred in connection with Initial Public Offering | 0— | 17,428 | ||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Prepaid expenses | (503,361 | ) | 0— | 88,726 | (840,249 | ) | ||||||||||
Accrued expenses | 358,986 | 0— | (110,104 | ) | 89,200 | |||||||||||
Net cash used in operating activities | (1,232,202 | ) | (177 | ) | (427,595 | ) | (971,316 | ) | ||||||||
Cash Flows from Investing Activities: | ||||||||||||||||
Investment in cash into Trust Account | $ | (172,500,000 | ) | 0— | 0— | (172,500,000 | ) | |||||||||
Net cash used in investing activities | (172,500,000 | ) | 0— | 0— | (172,500,000 | ) | ||||||||||
Cash Flows from Financing Activities: | ||||||||||||||||
Proceeds from sale of Units, net of underwriting discounts | 169,050,000 | 0— | 0— | 169,050,000 | ||||||||||||
Proceeds from sale of Private Placement Units | 4,750,000 | 0— | 0— | 4,750,000 | ||||||||||||
Proceeds from promissory note | 0— | 177 | ||||||||||||||
Proceeds from promissory note – related party | 469,759 | 0— | 390,000 | 350,000 | ||||||||||||
Repayment of promissory note – related party | (130,061 | ) | 0— | 0— | (85,302 | ) | ||||||||||
Payment of offering costs | (355,934 | ) | 0— | 0— | (355,934 | ) | ||||||||||
Net cash provided by financing activities | 173,783,764 | 177 | 390,000 | 173,708,764 | ||||||||||||
Net Change in Cash | 51,562 | 0— | (37,595 | ) | 237,448 | |||||||||||
Cash – Beginning of period | 0— | 0— | 67,689 | 0— | ||||||||||||
Cash – End of period | $ | 51,562 | $ | 0— | $ | 30,094 | $ | 237,448 | ||||||||
Non-cash investing and financing activities: | ||||||||||||||||
Offering costs included in accrued offering costs | $ | 0— | $ | 17,500 | ||||||||||||
Initial Classification of Warrant Liability | $ | 0— | $ | 187,625 | ||||||||||||
Issuance of Representative Shares/Founder Shares | $ | 0— | $ | 25,000 | ||||||||||||
Initial classification of warrant liabilities | 187,625 | 0— | ||||||||||||||
As Previously Reported | Adjustment related to Overallotment Liability | As Restated | ||||||||||
Condensed Balance Sheet at September 30, 2021 (unaudited) | ||||||||||||
Additional Paid in Capital | $ | 671,404 | $ | 117,244 | $ | 554,160 | ||||||
Accumulated deficit | $ | (1,247,997 | ) | $ | 117,244 | $ | (1,130,753 | ) | ||||
Condensed Statement of Operations for nine months ended September 30, 2021 (unaudited) | ||||||||||||
Transaction costs | $ | (567 | ) | $ | (16,861 | ) | $ | (17,428 | ) | |||
Change in fair value of overallotment liability | $ | 0— | $ | 134,105 | $ | 134,105 | ||||||
Net loss | $ | (1,247,370 | ) | $ | 117,244 | $ | (1,130,126 | ) | ||||
Statement of Cash Flows for nine months ended September 30, 2021 (unaudited) | ||||||||||||
Net loss | $ | 1,247,370 | ) | $ | 117,244 | $ | (1,130,126 | ) | ||||
Change in fair value of overallotment liability | $ | 0— | $ | (134,105 | ) | $ | (134,105 | ) | ||||
Transactions costs | $ | 567 | $ | 16,861 | $ | 17,428 | ||||||
Non Cash Financing and Investing Activities: | ||||||||||||
Accretion of common stock to redemption value | $ | (3,916,059 | ) | $ | (7,346,291 | ) | $ | (11,262,350 | ) |
Gross proceeds | $ | 172,500,000 | $ | 172,500,000 | ||||
Less: | ||||||||
Proceeds allocated to Public Warrants | 6,780,799 | (6,780,799 | ) | |||||
Common stock issuance costs | 3,733,189 | (3,733,189 | ) | |||||
Overallotment Liability | 748,362 | (748,362 | ) | |||||
Plus: | ||||||||
Adjustment of carrying value to redemption value | 11,262,350 | |||||||
Accretion of carrying value to redemption value | 11,262,350 | |||||||
Common stock subject to possible redemption | $ | 172,500,000 | $ | 172,500,000 | ||||
Three Months Ended September 30, 2021 | Nine Months Ended September 30, 2021 | For the Period From August 11, 2020 (Inception) Through September 30, 2020 | Three Months Ended March 31, | |||||||||||||||||
Basic and diluted net income ( loss) per common stock | ||||||||||||||||||||
2022 | 2021 | |||||||||||||||||||
Basic and diluted net loss per common stock | ||||||||||||||||||||
Numerator: | ||||||||||||||||||||
Allocation of net income (loss), as adjusted | $ | (797,811 | ) | $ | (1,130,126 | ) | $ | (177 | ) | |||||||||||
Allocation of net loss, as adjusted | $ | (40,109 | ) | $ | (40,950 | ) | ||||||||||||||
Denominator: | ||||||||||||||||||||
Basic and diluted weighted average shares outstanding | 22,037,500 | 19,320,330 | 3,750,000 | 22,037,500 | 13,795,417 | |||||||||||||||
Basic and diluted net income (loss) per common stock | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.00 | ) | |||||||||||
Basic and diluted net loss per common stock | $ | (0.00 | ) | $ | (0.00 | ) |
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |||
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |||
Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
Description | Level | September 30, 2021 | ||||||
Assets: | ||||||||
Marketable securities held in Trust Account | 1 | $ | 172,550,024 | |||||
Liabilities: | ||||||||
Warrant Liability – Private Placement Warrants | 3 | $ | 396,625 |
Description | Level | March 31, 2022 | December 31, 2021 | |||||||||
Assets: | ||||||||||||
Marketable securities held in Trust Account | 1 | $ | 172,625,112 | $ | 172,561,080 | |||||||
Liabilities: | ||||||||||||
Warrant Liability – Private Warrants | 3 | $ | 40,114 | $ | 342,190 |
Input | February 8, 2021 (Initial Measurement) | |||
Risk-free interest rate | 0.54 | % | ||
Effective expiration date | 6/23/2026 | |||
Dividend yield | 0.00 | % | ||
Expected volatility | 15.1 | % | ||
Exercise price | $ | 11.50 | ||
Unit Price | $ | 9.61 |
Input | December 31, 2021 | March 31, 2022 | ||||||
Risk-free interest rate | 1.18 | % | 2.44 | % | ||||
Effective expiration date (1) | 6/23/2026 | 6/23/2026 | ||||||
Dividend yield | 0.00 | % | 0.00 | % | ||||
Expected volatility | 10.6 | % | 4.8 | % | ||||
Exercise price | $ | 11.50 | $ | 11.50 | ||||
Unit Price | $ | 9.88 | $ | 9.77 | ||||
Probability of De-SPAC transaction | 75 | % | 90 | % |
Input | ||||
Risk-free interest rate | 0.92 | % | ||
Effective expiration date | 6/30/2026 | |||
Dividend yield | 0.00 | % | ||
Expected volatility | 13.7 | % | ||
Exercise price | $ | 11.50 | ||
Unit Price | $ | 9.96 |
(1) | The effective expiration date equals the probability-weighted average between a 2.0 year life of the warrants in the event there is no de-SPAC transaction and the contractual life if a transaction is closed. |
Private Warrant Liability | ||||
Fair value as of August 11, 2020 | $ | 0— | ||
Initial measurement on February 8, 2021 (IPO) | 169,850 | |||
Initial measurement on February 18, 2021 (Over allotment) | 17,775 | |||
Change in valuation inputs or other assumptions | 209,000 | |||
Fair value as of September 30, 2021 | $ | 396,625 | ||
Private Warrant Liability | ||||
Fair value as of December 31, 2021 | $ | 342,190 | ||
Change in fair value | (302,076 | ) | ||
Fair value as of March 31, 2022 | $ | 40,114 | ||
Overallotment Option | ||||
Fair value as of August 11, 2020 | $ | 0— | ||
Fair value at issuance February 8, 2021 | 748,362 | |||
Change in fair value February 18, 2021 | (134,105 | ) | ||
Elimination of overallotment liability February 18, 2021 | (614,257 | ) | ||
Fair Value at | $ | 0— | ||
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
Item 4. Controls and Procedures |
PART II—OTHER INFORMATION Item 1A. Risk Factors As of the date of this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosed in our Annual Report on Form 10-K, dated May 23, 2022 and Quarterly Report on Form10-Q for the quarter ended March 31, 2021, except as set forth below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.Changes in applicable laws or regulations, including the SEC’s proposed new rules regarding SPAC transactions (if adopted), or a failure to comply with any applicable laws and regulations, may adversely affect our business, including our ability to negotiate and complete our Business Combination and results of operations. We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our Business Combination and results of operations. On March 30, 2022, the SEC issued proposed rules relating to, among other items, enhancing disclosures in business combination transactions involving special purpose acquisition companies (“SPACs”) and private operating companies; amending the financial statement requirements applicable to transactions involving shell companies; effectively limiting the use of projections in SEC filings in connection with proposed business combination transactions; increasing the potential liability of certain participants in proposed business combination transactions; and the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940. These rules, if adopted, whether in the form proposed or in revised form, may materially adversely affect our ability to negotiate and complete our Business Combination and may significantly increase the costs and time related thereto. 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. |
Item 5. Other Information |
Item 6. Exhibits |
No. | Description of Exhibit | |
31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
31.2* | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
101.INS* | Inline XBRL Instance Document. | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* | Filed herewith. |
ASTREA ACQUISITION CORP. | ||||||
Date: August | By: | /s/ Felipe Gonzalez | ||||
Name: | Felipe Gonzalez | |||||
Title: | Chief Executive Officer and Director | |||||
(Principal Executive Officer) | ||||||
Date: August | By: | /s/ Jose Luis Cordova | ||||
Name: | Jose Luis Cordova | |||||
Title: | Chief Financial Officer and Director | |||||
(Principal Financial and Accounting Officer) |